Tempo Therapeutics lands $15 million Series B to push regenerative biomaterial toward market
What's the deal? Tempo Therapeutics, a San Diego clinical-stage regenerative medicine company, has closed an oversubscribed $14.5 million Series B led by Galaxy Sirius Partners. Johnson & Johnson's venture arm, JJDC, Gideon Strategic PartnersDealroom has a profile for this one. Try Dealroom →, Mesa Verde Venture PartnersDealroom has a profile for this one. Try Dealroom →, YK BioventuresDealroom has a profile for this one. Try Dealroom →, and other new and existing backers joined the round.
What's the endgame? Tempo builds synthetic biomaterials designed to help the body form healthy tissue. Its lead technology, Microporous Annealed Particle (MAP), acts as a temporary scaffold that supports regeneration before being replaced by the patient's own tissue.
Why now? The financing follows two milestones: publication of Tempo's first-in-human clinical study and submission of a De Novo application to the US Food and Drug Administration for its lead product. Proceeds will carry the surgical reconstruction program toward regulatory clearance and commercialisation.
What did the trial show? The randomised, controlled study treated 40 patients with full-thickness wounds after Mohs skin-cancer surgery. It met its primary safety endpoint, and at roughly six months MAP-treated wounds showed significantly improved scar quality against standard hydrocolloid care.
New leadership. Alongside the round, Tempo appointed Eric Richman to strengthen its leadership as it moves toward commercialisation. The company is also evaluating a second market for MAP in regenerative aesthetics, including tissue changes tied to weight loss and ageing.
"Tempo's MAP technology has the potential to improve surgical outcomes by supporting the regeneration of natural tissue," said Martin Sands, co-principal of Galaxy Sirius Partners.
The signal: At $14.5 million, the raise sits toward the smaller end of biotech financings, but it targets a clear near-term goal: FDA clearance and first revenue. For a clinical-stage company, a strategic backer like Johnson & Johnson signals confidence that a synthetic scaffold can move from trial data to standard of care.
Read more: pr-inside.com
Image credit: Generated with Gemini
